Umbilical cord blood graft engineering: challenges and opportunities

[1]  U. Gerdemann,et al.  Safety and Clinical Efficacy of Rapidly-Generated Virus-Specific T Cells with Activity Against Adv, EBV, CMV, HHV6 and BK Virus Administered after Allogeneic Hematopoietic Stem Cell Transplant , 2014 .

[2]  Sadik H. Kassim,et al.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.

[3]  M. Berg,et al.  Bringing natural killer cells to the clinic: ex vivo manipulation. , 2013, Hematology. American Society of Hematology. Education Program.

[4]  Jeffrey S. Miller.  Therapeutic applications: natural killer cells in the clinic. , 2013, Hematology. American Society of Hematology. Education Program.

[5]  R. Krance,et al.  Multi-Virus-Specific T-Cell Therapy For Patients After Hematopoietic Stem Cell and Cord Blood Transplantation , 2013 .

[6]  S. Parmar,et al.  Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment , 2013 .

[7]  E. Shpall,et al.  Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor , 2013 .

[8]  L. Zon,et al.  Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. , 2013, Blood.

[9]  C. Cruz,et al.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.

[10]  S. Maiella,et al.  Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. , 2013, Blood.

[11]  J. Ritz,et al.  Tregs, HSCT, and acute GVHD: up close and personal. , 2013, Blood.

[12]  K. Ballen,et al.  Umbilical cord blood transplantation: the first 25 years and beyond. , 2013, Blood.

[13]  D. Hanau,et al.  Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d’Histocompatibilité et d’Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire ( , 2013, Haematologica.

[14]  S. Pai,et al.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. , 2013, Blood.

[15]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[16]  R. Sposto,et al.  Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy , 2013, Clinical Cancer Research.

[17]  D. McKenna,et al.  Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products , 2013, Transfusion.

[18]  Mark Munsell,et al.  Cord-blood engraftment with ex vivo mesenchymal-cell coculture. , 2012, The New England journal of medicine.

[19]  T. Fry,et al.  Early Clinical Experience of aAPC Activated NK-DLI Following Allogeneic PBSCT in Pediatric Solid Tumor Patients. , 2012 .

[20]  D. Campana,et al.  Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order , 2012 .

[21]  R. Schlenk,et al.  Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems , 2012 .

[22]  Elaine Coustan-Smith,et al.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. , 2012, Cytotherapy.

[23]  J. Chewning,et al.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. , 2012, The New England journal of medicine.

[24]  H. Kohrt,et al.  Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. , 2012, Blood.

[25]  E. Shpall,et al.  Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. , 2012, Experimental hematology.

[26]  Mingyao Liu,et al.  Amelioration of acute graft‐versus‐host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model , 2012, Transfusion.

[27]  Dean Anthony Lee,et al.  Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. , 2012, Blood.

[28]  S. Rosenberg,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[29]  J. Teruya-Feldstein,et al.  Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. , 2012, Blood.

[30]  L. Hurton,et al.  Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.

[31]  A. Nagler,et al.  Nicotinamide, a Form of Vitamin B3, Promotes Expansion of Natural Killer Cells That Display Increased In Vivo Survival and Cytotoxic Activity, , 2011 .

[32]  D. Munn,et al.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? , 2011, Blood.

[33]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[34]  J. Cayuela,et al.  Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high‐risk hematological diseases , 2011, Transplant infectious disease : an official journal of the Transplantation Society.

[35]  M. Baccarani,et al.  Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.

[36]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[37]  Harry Dolstra,et al.  Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process , 2011, PloS one.

[38]  M. Asaka,et al.  Expansion of CD4+CD25+ regulatory T cells from cord blood CD4+ cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin , 2011, Annals of Hematology.

[39]  James M. Harris,et al.  Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. , 2011, Cell stem cell.

[40]  D. Landau,et al.  Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention. , 2011, Blood.

[41]  M. Sabatino,et al.  Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells , 2011, Journal of immunotherapy.

[42]  Dean Anthony Lee,et al.  Expansion, purification, and functional assessment of human peripheral blood NK cells. , 2011, Journal of visualized experiments : JoVE.

[43]  J. Wagner,et al.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.

[44]  A. Leen,et al.  How I treat adenovirus in hematopoietic stem cell transplant recipients. , 2010, Blood.

[45]  J. Melenhorst,et al.  Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. , 2010, Blood.

[46]  Colleen Delaney,et al.  Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. , 2010, Blood.

[47]  H. Einsele,et al.  Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. , 2010, Blood.

[48]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[49]  Christophe Benoist,et al.  Stability of the Regulatory T Cell Lineage in Vivo , 2010, Science.

[50]  J. Gribben,et al.  Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion , 2010, Journal of immunotherapy.

[51]  J. Wagner,et al.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. , 2010, The Lancet. Oncology.

[52]  G. Ledderose,et al.  Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. , 2010, Blood.

[53]  P. Hanley,et al.  Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. , 2010, Blood.

[54]  R. Arceci,et al.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. , 2010, Blood.

[55]  Colleen Delaney,et al.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution , 2010, Nature Medicine.

[56]  T. Brismar,et al.  A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation , 2010, Cancer Immunology, Immunotherapy.

[57]  A. Scaradavou,et al.  HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection. , 2009, Blood.

[58]  M. Berg,et al.  In Vitro Expanded NK Cells Have Increased Natural Cytotoxity Receptors, TRAIL and NKG2D Expression, and Superior Tumor Cytotoxicity Compared to Short-Term IL-2 –Activated NK Cells. , 2009 .

[59]  J. Wagner,et al.  Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. , 2009, Blood.

[60]  P. Hanley,et al.  Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. , 2009, Blood.

[61]  H. Heslop.  How I treat EBV lymphoproliferation. , 2009, Blood.

[62]  M. Kuo,et al.  The regulatory function of umbilical cord blood CD4+ CD25+ T cells stimulated with anti‐CD3/anti‐CD28 and exogenous interleukin (IL)‐2 or IL‐15 , 2009, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[63]  D. Munn,et al.  Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. , 2009, Blood.

[64]  J. Wagner,et al.  Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood , 2009, British journal of haematology.

[65]  E. Gluckman,et al.  Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft‐ and transplantation‐related factors , 2009, British journal of haematology.

[66]  M. Berg,et al.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. , 2009, Cytotherapy.

[67]  M. Boeckh,et al.  How we treat cytomegalovirus in hematopoietic cell transplant recipients. , 2009, Blood.

[68]  J. Sampath,et al.  Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. , 2009, Blood.

[69]  D. Campana,et al.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.

[70]  J. Wagner,et al.  Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. , 2009, Blood.

[71]  J. D. Di Santo,et al.  IL-15 trans-presentation promotes human NK cell development and differentiation in vivo , 2009, The Journal of experimental medicine.

[72]  Peter Parham,et al.  Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. , 2009, Blood.

[73]  Yiqun Zhang,et al.  Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[74]  A. Scheffold,et al.  IL‐2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells , 2008, European journal of immunology.

[75]  M. Bachmann,et al.  The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. , 2008, Blood.

[76]  E. Shpall,et al.  Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. , 2007, Blood.

[77]  J. Klein,et al.  The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. , 2007, Blood.

[78]  S. Barry,et al.  Isolation, propagation and characterization of cord blood derived CD4+ CD25+ regulatory T cells. , 2007, Journal of immunological methods.

[79]  J. Wagner,et al.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. , 2007, Blood.

[80]  J. Klein,et al.  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study , 2007, The Lancet.

[81]  C. Contag,et al.  In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. , 2007, Blood.

[82]  L. Lefrançois,et al.  Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity In Vivo1 , 2006, The Journal of Immunology.

[83]  J. Wagner,et al.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. , 2006, Blood.

[84]  J. Wagner,et al.  Double umbilical cord blood transplantation. , 2006, Current opinion in immunology.

[85]  Chung-Che Chang,et al.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals , 2006, Nature Medicine.

[86]  K. Rezvani,et al.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. , 2006, Blood.

[87]  T. Lion,et al.  Safe adoptive transfer of virus‐specific T‐cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation , 2006, British journal of haematology.

[88]  E. Thiel,et al.  Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. , 2006, Blood.

[89]  E. Shpall,et al.  Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells , 2006, Bone Marrow Transplantation.

[90]  I. Bernstein,et al.  Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. , 2005, Blood.

[91]  J. Ritz,et al.  Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. , 2005, Blood.

[92]  C. Craddock,et al.  Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers , 2005, The Journal of experimental medicine.

[93]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[94]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[95]  Todd E DeFor,et al.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. , 2005, Blood.

[96]  P. Frenette,et al.  Enforced fucosylation of neonatal CD34+ cells generates selectin ligands that enhance the initial interactions with microvessels but not homing to bone marrow. , 2005, Blood.

[97]  M. Labopin,et al.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. , 2004, The New England journal of medicine.

[98]  J. Wagner,et al.  Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. , 2004, The New England journal of medicine.

[99]  B. Levine,et al.  Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. , 2004, Blood.

[100]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[101]  L. Xia,et al.  Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. , 2004, Blood.

[102]  C. Thoburn,et al.  Association of Foxp3 regulatory gene expression with graft-versus-host disease. , 2004, Blood.

[103]  D. Klatzmann,et al.  Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. , 2003, The Journal of clinical investigation.

[104]  P. Moss,et al.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines , 2003, The Lancet.

[105]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[106]  J. Kurtzberg,et al.  Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. , 2003, Blood.

[107]  R. Cummings,et al.  Discordant expression of selectin ligands and sialyl Lewis x-related epitopes on murine myeloid cells. , 2002, Blood.

[108]  M. Salavert,et al.  Early infections in adult patients undergoing unrelated donor cord blood transplantation , 2002, Bone Marrow Transplantation.

[109]  I. Bernstein,et al.  Delta-1 enhances marrow and thymus repopulating ability of human CD34(+)CD38(-) cord blood cells. , 2002, The Journal of clinical investigation.

[110]  J Wagner,et al.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. , 2002, Blood.

[111]  C. Fathman,et al.  Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.

[112]  A. Rudin,et al.  Characterization of human CD25+ CD4+ T cells in thymus,
cord and adult blood , 2002, Immunology.

[113]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[114]  D. Rizzieri,et al.  Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[115]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[116]  B. Storer,et al.  Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. , 2001, The New England journal of medicine.

[117]  A. Nagler,et al.  Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen , 2001, Bone Marrow Transplantation.

[118]  J. Wagner,et al.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. , 2001, The New England journal of medicine.

[119]  A. Zander,et al.  Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. , 2001, Blood.

[120]  I. Bernstein,et al.  Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling , 2000, Nature Medicine.

[121]  J. Klein,et al.  Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. , 2000, The New England journal of medicine.

[122]  F Locatelli,et al.  Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. , 1999, Blood.

[123]  J. Adamson,et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. , 1998, The New England journal of medicine.

[124]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[125]  P. Henslee-Downey,et al.  Use of partially mismatched related donors extends access to allogeneic marrow transplant. , 1997, Blood.

[126]  J. Kurtzberg,et al.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. , 1996, The New England journal of medicine.

[127]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[128]  R. McEver,et al.  Leukocyte trafficking mediated by selectin-carbohydrate interactions , 1995, The Journal of Biological Chemistry.

[129]  I. Bernstein,et al.  A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors. , 1994, Blood.

[130]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[131]  J. Kurtzberg,et al.  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. , 1989, The New England journal of medicine.

[132]  S. Parmar,et al.  Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. , 2014, Cytotherapy.

[133]  S. Stevanović,et al.  Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  麻生 裕紀.  Prostaglandin E[2] enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells , 2012 .

[135]  C. Zhang,et al.  Human umbilical cord blood-derived stromal cells prevent graft-versus-host disease in mice following haplo-identical stem cell transplantation. , 2011, Cytotherapy.

[136]  I. Bernstein,et al.  Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8 (cid:1) T-cell response against the nonengrafted unit , 2010 .

[137]  B. Yeap,et al.  Double unrelated reduced-intensity umbilical cord blood transplantation in adults. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[138]  Leo Lefrançois,et al.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. , 2006, Journal of immunology.

[139]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. , 1997, The New England journal of medicine.